Tonix Pharmaceuticals Hol... (TNXP)
NASDAQ: TNXP
· Real-Time Price · USD
32.73
0.37 (1.14%)
At close: Jun 23, 2025, 3:59 PM
33.57
2.55%
Pre-market: Jun 24, 2025, 06:27 AM EDT
1.14% (1D)
| Bid | 33.56 |
| Market Cap | 240.84M |
| Revenue (ttm) | 10.04M |
| Net Income (ttm) | -115.1M |
| EPS (ttm) | 356.28 |
| PE Ratio (ttm) | 0.09 |
| Forward PE | -5.35 |
| Analyst | Strong Buy |
| Ask | 33.8 |
| Volume | 498,376 |
| Avg. Volume (20D) | 1,112,383 |
| Open | 32.80 |
| Previous Close | 32.36 |
| Day's Range | 30.84 - 32.97 |
| 52-Week Range | 6.76 - 131.00 |
| Beta | 2.10 |
About TNXP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TNXP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TNXP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Tonix Pharmaceuticals Holding Corp. is scheduled to release its earnings on Aug 15, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
-8.41%
Tonix Pharmaceuticals shares are trading lower aft...
Unlock content with
Pro Subscription
3 months ago
+32.48%
Tonix Pharmaceutical shares are trading higher after the company announced the FDA will not require an advisory committee for Tnx-102 SL.
3 months ago · seekingalpha.com
Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 YearsPDUFA date of August 15th of 2025 set to review on whether or not TNX-102 SL should be approved to treat patients with Fibromyalgia. The company announced that the FDA will not require an Advisory Com...
